Clin. eff. & PROs in mod.-sev. AD pts treated w/ oral systemics: 12-wk interim results from AD-REAL focusing on pts w/ BSA 7 ('itch dominant')


Por: Augustin, M, Serra-Baldrich, E, Seneschal, J, Elrayes, M, Otero-Asman, JR, Berkery, E, Fakouri, W, Bewley, A, Garcia-Latasa, J, Pinter, A, Schlöbe, A

Publicada: 1 abr 2025
Resumen:


Filiaciones:
Augustin, M:
 Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

Serra-Baldrich, E:
 Univ Autonoma Barcelona, Hosp St Pau, Dept Dermatol, Cutaneous Allergy Unit, Barcelona, Spain

Seneschal, J:
 Univ Bordeaux, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol, Bordeaux, France

Elrayes, M:
 Eli Lilly & Co, Indianapolis, IN USA

Otero-Asman, JR:
 Eli Lilly & Co, Indianapolis, IN USA

Berkery, E:
 Eli Lilly & Co, Indianapolis, IN USA

Fakouri, W:
 Eli Lilly & Co, Indianapolis, IN USA

Bewley, A:
 Royal London Hosp, Dept Dermatol, London, England

Garcia-Latasa, J:
 Ctr Especial Med Grande Covian, Zaragoza, Spain

Pinter, A:
 Univ Hosp Frankfurt, Venereol & Allergol, Frankfurt, Germany

Schlöbe, A:
 Lilly Deutschland, Bad Homburg, Germany
ISSN: 16100379





JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Alemania
Tipo de documento: Meeting Abstract
Volumen: 23 Número:
Páginas:
WOS Id: 001515598600307

MÉTRICAS